Significant Milestone for Sisram Medical
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio
As a global wellness leader, Sisram Medical Ltd has successfully passed critical testing for its innovative product, DAXXIFY. This advancement underscores Sisram's commitment to excellence in the medical aesthetic field.
Launch of DAXXIFY: What to Expect
DAXXIFY, the world's first long-acting peptide-formulated neuromodulator, has now successfully completed quality testing mandated by the National Institutes for Food and Drug Control in China. This important step further validates DAXXIFY's status as a safe and effective solution for the treatment of moderate to severe glabellar lines, as it meets the comprehensive quality standards set by regulatory authorities.
Utilizing proprietary Peptide Exchange Technology, DAXXIFY provides both a rapid onset of action and an extended duration of effect. This means not only quicker results for consumers but also lasting effects that set it apart from existing offerings in the market.
Strategic Initiatives and Market Readiness
In preparation for DAXXIFY's market launch, Sisram has put together a robust team dedicated to various aspects of the commercialization process. This includes proficient sales and marketing professionals focusing on building essential relationships with medical aesthetic institutions, enhancing market access, and ensuring educational support for healthcare providers.
The Company's operational strategy is further reinforced through partnerships with industry leaders like Fosun Wanbang and Shanghai Pharmaceuticals. These alliances enable Sisram to create a transparent, reliable supply chain that guarantees quality from production to clinical application. This systematic approach is integral to fulfilling market demands efficiently and maintaining high standards across all operational layers.
Revolutionizing the Aesthetic Market
As the first injectable treatment of its kind in mainland China, DAXXIFY represents a transformative offering for patients seeking superior aesthetic solutions. The completion of regulatory testing signifies a milestone that prepares Sisram for an impactful market entry, particularly appealing to consumers prioritizing quality in their self-care treatments.
With a strong strategic foundation and operational excellence, Sisram anticipates that DAXXIFY will play a pivotal role in its injectable portfolio, fueling business growth and allowing the Company to explore additional revenue opportunities within the wellness sector.
About Sisram Medical Ltd
Sisram Medical Ltd stands out as a champion of medical aesthetic innovation with a rich history spanning over 25 years. With a diversified offering that includes Energy-Based Devices, injectables, and diagnostics, Sisram has cemented its reputation as a global leader. The Company operates across more than 110 regions, offering award-winning products that define new benchmarks in patient safety, efficacy, and quality.
Majority-owned by Fosun Pharma, Sisram is listed on the Hong Kong Stock Exchange, reflecting its commitment to transparency and excellence in the healthcare market.
Frequently Asked Questions
What is DAXXIFY?
DAXXIFY is a long-acting neuromodulator designed for medical aesthetics, specifically for treating moderate to severe glabellar lines.
What recent milestone has Sisram Medical achieved?
Sisram Medical has successfully passed NIFDC quality testing for DAXXIFY in mainland China, enabling it to move towards market launch.
What technology does DAXXIFY utilize?
DAXXIFY employs proprietary Peptide Exchange Technology, which enhances both its efficacy and safety profile.
How is Sisram preparing for DAXXIFY's launch?
The company has formed a dedicated team to manage market expansion, clinical support, and strong supply chain partnerships.
What is Sisram’s vision for the future?
Sisram aims to solidify its position in the aesthetics sector, leveraging DAXXIFY as a core component of its growth strategy.
